Lag­gard Lil­ly says its CDK 4/6 drug abe­maci­clib scored in PhI­II, while ri­vals at No­var­tis, Pfiz­er sharp­en their knives

Just a week af­ter No­var­tis scored a key ap­proval for its CDK 4/6 can­cer drug, Eli Lil­ly is an­nounc­ing that its long-await­ed Phase III read­out for its ri­val drug abe­maci­clib looks good. We won’t get the da­ta un­til lat­er, but the phar­ma gi­ant says its MONARCH-2 tri­al comes with pos­i­tive pro­gres­sion-free da­ta on ad­vanced hor­mone-re­cep­tor-pos­i­tive, HER2 neg­a­tive breast can­cer.

In­ves­ti­ga­tors com­pared abe­maci­clib com­bined with ful­ves­trant to ful­ves­trant alone. And the da­ta set up an FDA fil­ing some­time in the next three months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER